York Health Economics Consortium Ltd., University of York, UK.
Int J Clin Pract. 2010 May;64(6):775-83. doi: 10.1111/j.1742-1241.2010.02349.x. Epub 2010 Mar 29.
As obesity prevalence and health-care costs increase, Health Care providers must prevent and manage obesity cost-effectively.
Using the 2006 NICE obesity health economic model, a primary care weight management programme (Counterweight) was analysed, evaluating costs and outcomes associated with weight gain for three obesity-related conditions (type 2 diabetes, coronary heart disease, colon cancer). Sensitivity analyses examined different scenarios of weight loss and background (untreated) weight gain.
Mean weight changes in Counterweight attenders was -3 kg and -2.3 kg at 12 and 24 months, both 4 kg below the expected 1 kg/year background weight gain. Counterweight delivery cost was pound59.83 per patient entered. Even assuming drop-outs/non-attenders at 12 months (55%) lost no weight and gained at the background rate, Counterweight was 'dominant' (cost-saving) under 'base-case scenario', where 12-month achieved weight loss was entirely regained over the next 2 years, returning to the expected background weight gain of 1 kg/year. Quality-adjusted Life-Year cost was pound2017 where background weight gain was limited to 0.5 kg/year, and pound2651 at 0.3 kg/year. Under a 'best-case scenario', where weights of 12-month-attenders were assumed thereafter to rise at the background rate, 4 kg below non-intervention trajectory (very close to the observed weight change), Counterweight remained 'dominant' with background weight gains 1 kg, 0.5 kg or 0.3 kg/year.
Weight management for obesity in primary care is highly cost-effective even considering only three clinical consequences. Reduced healthcare resources use could offset the total cost of providing the Counterweight Programme, as well as bringing multiple health and Quality of Life benefits.
随着肥胖症患病率和医疗保健成本的增加,医疗保健提供者必须有效地预防和管理肥胖症。
使用 2006 年 NICE 肥胖症健康经济模型,分析了一个初级保健体重管理计划(Counterweight),评估了与三种肥胖相关疾病(2 型糖尿病、冠心病、结肠癌)体重增加相关的成本和结果。敏感性分析检查了不同的减肥方案和背景(未经治疗)体重增加情况。
Counterweight 参与者的平均体重变化在 12 个月和 24 个月时分别为-3 公斤和-2.3 公斤,均比预期的每年 1 公斤的背景体重增加低 4 公斤。Counterweight 的每位患者的治疗成本为 59.83 英镑。即使假设 12 个月时的脱落/未参与者(55%)没有减肥且按背景速度增加体重,在“基本情况”下,Counterweight 仍然是“有利可图的”(节省成本),即 12 个月时实现的减肥在接下来的 2 年内完全恢复,回到每年预期的背景体重增加 1 公斤。当背景体重增加限制在每年 0.5 公斤时,质量调整生命年的成本为 2017 英镑,而当背景体重增加限制在每年 0.3 公斤时,质量调整生命年的成本为 2651 英镑。在“最佳情况”下,假设此后 12 个月参与者的体重按背景速度增加,比不干预轨迹低 4 公斤(非常接近观察到的体重变化),Counterweight 仍然“有利可图”,背景体重增加 1 公斤、0.5 公斤或 0.3 公斤/年。
即使仅考虑三种临床后果,初级保健中的肥胖症管理也是高度符合成本效益的。减少医疗资源的使用可以抵消提供 Counterweight 计划的总成本,同时带来多项健康和生活质量收益。